CHRNA7 and Crush Syndrome: Another investigation on the combined use of anisodamine and neostigmine also demonstrated their effect on serum potassium decrease in crush syndrome, which depended on the role of α7nAChR in increasing the phosphorylation of Janus kinase two and signal transducer and activator of transcription 3 (Xu et al., 2016).